Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04, FiscalAI reports.
Kairos Pharma Stock Down 5.6%
NYSEAMERICAN:KAPA traded down $0.03 during trading hours on Friday, hitting $0.45. 12,561 shares of the company traded hands, compared to its average volume of 219,114. The company has a market cap of $1.54 million, a PE ratio of -0.23 and a beta of 1.85. The firm’s 50-day simple moving average is $1.10 and its 200-day simple moving average is $2.83. Kairos Pharma has a one year low of $0.42 and a one year high of $7.28.
About Kairos Pharma
Kairos Pharma, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to address immune suppression and treatment resistance within the tumor microenvironment. The company’s research is centered on immuno-oncology approaches intended to improve the body’s ability to recognize and attack cancer cells. Kairos Pharma is developing a pipeline of investigational therapies, including antibody-based and small-molecule programs aimed at biological pathways associated with tumor growth, immune evasion and resistance to existing treatments.
Featured Stories
- Five stocks we like better than Kairos Pharma
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
